At tomorrow’s Social Innovation Summit, Claudia Carravetta, our VP of corporate responsibility and president of the AbbVie Foundation, will be speaking with MATTER's Steven Collins about our collective effort to advance #HealthEquity through innovative solutions. Learn more about the summit and see the full agenda: https://bit.ly/3R6VAb5 #SIS24
About us
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
- Website
-
http://www.abbvie.com
External link for AbbVie
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- North Chicago, Illinois
- Type
- Public Company
- Specialties
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care
Locations
Employees at AbbVie
Updates
-
#IBD is a complex set of diseases, meaning patients have diverse needs. Through ongoing research and development, we’re working to find solutions to help them manage their disease. Read how: https://bit.ly/3x01p3b #UlcerativeColitis #Crohns [Image description: Sofie Berg, Pharm.D., Ph.D., Therapeutic Area Head, International Immunology, International Medical Affairs, AbbVie, says, “We are motivated to bring new treatment options to patients in need through our commitment to ongoing research and development in gastroenterology.”]
-
Conferences and meetings like #ASCO24 are a great opportunity to network, connect with #recruiters and discuss your career goals. Hear two of our senior recruiters share a few tips on how to prepare ahead of attending a large meeting and learn more about our #career opportunities: https://bit.ly/4aJZZrw [Video description: Two recruiters attending a meeting and putting on event badges, setting up, sharing advice and waving with colleagues.]
-
At #ASCO24, we’ll be presenting data from Phase 1 studies of #ADCs in patients with advanced solid tumors, and in patients with advanced colorectal #cancer. Learn about our differentiated approach to developing solid tumor research: https://bit.ly/3VmBpsc
-
To welcome #PrideMonth, we asked members of our PRIDE employee resource group (ERG) to share some of their intersecting identities and what supporting the #LGBTQ+ community means to them. Learn how this ERG fosters an inclusive space for our employees year-round: https://bit.ly/3R8ZyQh #BelongAtAbbVie [Video description: AbbVie employees sharing their identities, orientation, participation in and/or support of the LGBTQ+ community to celebrate Pride Month.]
-
NEWS: The European Medicines Agency's #CHMP granted a positive opinion for our investigational treatment in #UlcerativeColitis. Read more: https://bit.ly/4bDSiUJ #IBD [Video description: On-screen text reads, “Immunology News. Positive CHMP Opinion in Ulcerative Colitis.”]
-
Attending #ASCO24? Meet with our team of experts working to transform the standards of care for #cancer patients. Explore our career opportunities in #oncology: https://bit.ly/4bZsAtG
-
Over the past decade, new approaches and innovation have enabled scientists to reimagine #BloodCancer research – but there's more to discover. See why our scientists won’t settle when it comes to treating #cancer. https://bit.ly/3V2ggSv #WorldBloodCancerDay
-
JUST IN: We’re presenting three oral abstracts at #ASCO24 highlighting new data from our #ADC platform in #SolidTumors with high unmet needs. Read more: https://bit.ly/4bS231q [Video description: On-screen text reads, “Oncology News.”]
Affiliated pages
Similar pages
Browse jobs
Stock
ABBV
NYSE
20 minutes delay
$163.03
1.79 (1.11%)
- Open
- 159.48
- Low
- 158.83
- High
- 163.19
Data from Refinitiv
See more info on